Transfidelity

Development of first-in-class disease-modifying therapy against age-related neuropathology disorders (Alzheimer's, Parkinson's) VENTURE KICK STAGE 1 WINNER! First-in-class disease-modifying therapy targeting age-related error-prone translation resulted in pathogenic protein misfolding and loss of proteostasis leading to neurotoxicity and age-related neurodegenerative disorders. Focus on Parkinson’s disease with expansion potential to other proteinopathies such as Alzheimer’s disease. Targets validation in human-relevant models and compound optimization ongoing.